ID

38231

Descrição

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours; ODM derived from: https://clinicaltrials.gov/show/NCT01493336

Link

https://clinicaltrials.gov/show/NCT01493336

Palavras-chave

Versões (1)
  1. 30/09/2019 30/09/2019 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

30 de setembro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

Inglês

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients,>/= 18 years of age
Descrição

Adult | Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
histological/cytological confirmation of colorectal or breast cancer
Descrição

Colorectal Carcinoma | Breast Carcinoma

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009402
UMLS CUI [2]
C0678222
patient is ambulatory and has a karnofsky performance status of > 70%
Descrição

Patient Ambulatory | Karnofsky Performance Status

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0439841
UMLS CUI [2]
C0206065
body surface area between 1.5 and 2.0 m2
Descrição

Body Surface Area

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0005902
either:
Descrição

Either

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3844638
due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
Descrição

Etiology | Xeloda | Combined Modality Therapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0015127
UMLS CUI [2]
C0724419
UMLS CUI [3]
C0009429
currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2
Descrição

Xeloda | Ability Receive Investigational New Drugs

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0724419
UMLS CUI [2,1]
C0085732
UMLS CUI [2,2]
C1514756
UMLS CUI [2,3]
C0013230
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
any contraindication to xeloda
Descrição

Medical contraindication Xeloda

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0724419
received xeloda in the 6 days prior to day 1
Descrição

Xeloda Received Recently

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0724419
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C0332185
subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
Descrição

Organ allografts | Exception Autologous bone marrow transplant Post High-dose chemotherapy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0178784
UMLS CUI [1,2]
C0040739
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0194037
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C1328050
renal impairment
Descrição

Renal Insufficiency

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1565489
pregnant or lactating females
Descrição

Pregnancy | Breast Feeding

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
participation in an investigational drug study within 28 days prior to screening
Descrição

Study Subject Participation Status | Investigational New Drugs

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
Descrição

Lacking Integrity Upper Gastrointestinal Tract | Malabsorption Syndrome

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C1947912
UMLS CUI [1,3]
C3203348
UMLS CUI [2]
C0024523
serious uncontrolled intercurrent infections
Descrição

Communicable Diseases Serious Uncontrolled

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0205318
history of clinically significant coronary artery disease
Descrição

Coronary Artery Disease

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1956346
concomitant treatment with warfarin
Descrição

Warfarin therapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C4303340
known dihydropyrimidine dehydrogenase deficiency
Descrição

Dihydropyrimidine Dehydrogenase Deficiency

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1959620
Voltar ao início da página

Similar models

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients,>/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Colorectal Carcinoma | Breast Carcinoma
Item
histological/cytological confirmation of colorectal or breast cancer
boolean
C0009402 (UMLS CUI [1])
C0678222 (UMLS CUI [2])
Patient Ambulatory | Karnofsky Performance Status
Item
patient is ambulatory and has a karnofsky performance status of > 70%
boolean
C0030705 (UMLS CUI [1,1])
C0439841 (UMLS CUI [1,2])
C0206065 (UMLS CUI [2])
Body Surface Area
Item
body surface area between 1.5 and 2.0 m2
boolean
C0005902 (UMLS CUI [1])
Either
Item
either:
boolean
C3844638 (UMLS CUI [1])
Etiology | Xeloda | Combined Modality Therapy
Item
due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
boolean
C0015127 (UMLS CUI [1])
C0724419 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Xeloda | Ability Receive Investigational New Drugs
Item
currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2
boolean
C0724419 (UMLS CUI [1])
C0085732 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Xeloda
Item
any contraindication to xeloda
boolean
C1301624 (UMLS CUI [1,1])
C0724419 (UMLS CUI [1,2])
Xeloda Received Recently
Item
received xeloda in the 6 days prior to day 1
boolean
C0724419 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
Organ allografts | Exception Autologous bone marrow transplant Post High-dose chemotherapy
Item
subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
boolean
C0178784 (UMLS CUI [1,1])
C0040739 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0194037 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1328050 (UMLS CUI [2,4])
Renal Insufficiency
Item
renal impairment
boolean
C1565489 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
participation in an investigational drug study within 28 days prior to screening
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Lacking Integrity Upper Gastrointestinal Tract | Malabsorption Syndrome
Item
lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
boolean
C0332268 (UMLS CUI [1,1])
C1947912 (UMLS CUI [1,2])
C3203348 (UMLS CUI [1,3])
C0024523 (UMLS CUI [2])
Communicable Diseases Serious Uncontrolled
Item
serious uncontrolled intercurrent infections
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Coronary Artery Disease
Item
history of clinically significant coronary artery disease
boolean
C1956346 (UMLS CUI [1])
Warfarin therapy
Item
concomitant treatment with warfarin
boolean
C4303340 (UMLS CUI [1])
Dihydropyrimidine Dehydrogenase Deficiency
Item
known dihydropyrimidine dehydrogenase deficiency
boolean
C1959620 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial